Hyperinsulinemia is a predictor of new cardiovascular events in Colombian patients with a first myocardial infarction

International Journal of Cardiology

Volumn 148, Issue 1, 2011, Pages 85-90

  García, Ronald G ^a   Rincón, Melvin Y ^a   Arenas, William D ^a   Silva, Sandra Y ^a   Reyes, Laura M ^a   Ruiz, Silvia L ^a   Ramirez, Fabián ^a   Camacho, Paul A ^a   Luengas, Carlos ^a   Saaibi, José F ^a   Balestrini, Sebastián ^a   Morillo, Carlos ^b   López Jaramillo, Patricio ^a,c  

^a FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSIDAD DE SANTANDER   (Colombia)

Author keywords

Acute myocardial infarction; Colombia; Hyperinsulinism; Prognosis; Recurrence

Indexed keywords

INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COLOMBIA; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HEART FAILURE; HEART RATE; HUMAN; HYPERINSULINEMIA; HYPERINSULINISM; HYPERTENSION; INCIDENCE; INCOME; INSULIN RESISTANCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; COLOMBIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERINSULINISM; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79952819314     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.10.030     Document Type: Article

References (56)

1. World Health Organization. Available at: http://www.who.int/ cardiovascular-diseases/en/cvd-atlas-14-deathHD.pdf.
2. World Health Organization. Global burden of coronary heart disease. The atlas of heart disease and stroke. Available at: http://www.who.int/ cardiovascular-diseases/ en/cvd-atlas-13-coronaryHD.pdf 2006.
3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-53. (Pubitemid 33108145)
4. Lopez AD. Assessing the burden of mortality from cardiovascular diseases. World Health Stat Q 1993;46:91-6. (Pubitemid 24017907)
5. Lopez-Jaramillo P, Casas JP, Bautista L, Serrano NC, Morillo CA. An integrated proposal to explain the epidemic of cardiovascular disease in a developing country. From socioeconomic factors to free radicals. Cardiology 2001;96:1-6. (Pubitemid 33035951)
6. Vickrey B, Rector T, Wickstrom S, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901.
7. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study. Lancet 2004;364:937-52.
8. Lanas F, Avezum A, Bautista LE, et al. INTERHEART investigators in Latin America. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007;115:1067-74.
9. PerezM, Casas JP, Cubillos-Garzón LA, et al. Usingwaist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil 2003;10:328-35. (Pubitemid 38037247)
10. Rueda-Clausen CF, Silva FA, López-Jaramillo P. Epidemic of overweight and obesity in Latin America and the Caribbean. Int J Cardiol 2008;125:111-2. (Pubitemid 351305406)
11. Lopez-Jaramillo P, Casas JP, Morillo CA. C reactive protein and cardiovascular diseases in Andean population. Circulation 2002;105:l10.
12. Garcia RG, Cifuentes AE, Caballero RS, Sanchez L, López-Jaramillo P. A proposal for an appropriate central obesity diagnosis in Latin American population. Int J Cardiol 2006;110:263-4.
13. López-Jaramillo P, Rueda-Clausen CF, Silva FA. The utility of different definitions of metabolic syndrome in Andean population. Int J Cardiol 2007;116:421-2.
14. Ramírez F, García RG, Silva F, López-Jaramillo P, Villa-Roel C. Glicemia en ayuno alterada es el factor de riesgo más sensible de enfermedad aterosclerótica coronaria en pacientes colombianos con angina pectoris. Acta Med Colomb 2004;29:302-11.
15. Kaplan R, Heckbert S, Furberg C, Psaty BM. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002;55:654-64. (Pubitemid 34831058)
16. Wong ND, Cupples LA, Ostfeld AM, Levy D, Kannel WB. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol 1989;130:469-80. (Pubitemid 19214613)
17. Leander K, Wiman B, Hallqvist J, Andersson T, Ahlbom A, de Faire Ul. Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program. Eur J Cardiovasc Rehabil 2007;14:532-7. (Pubitemid 47229735)
18. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations. Circulation 1999;100:1016-30.
19. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res Suppl 1985;15:41-6.
20. Després JP, Lamarche B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7. (Pubitemid 26114161)
21. Yarnell JW, Sweetnam PM, Marks V, Teale JD, Bolton CH. Insulin in ischaemic heart disease: are associations explained by triglyceride concentrations? The Caerphilly prospective study. Br Heart J 1994;71:293-6.
22. Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000;20:538-44. (Pubitemid 30086114)
23. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980;19:205-10. (Pubitemid 10003180)
24. Yanase M, Takatsu F, Tagawa T, et al. Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance. Circ J 2004;68:47-52. (Pubitemid 38139936)
25. Sönmez K, Pala S, Mutlu B, et al. Distribution of risk factors according to socioeconomic status in male and female cases with coronary artery disease. Am J Epidemiol 2004;159(7):655-62.
26. Sundquist K, Winkleby M, Ahlén H, Johansson SE. Neighborhood socioeconomic environment and incidence of coronary heart disease: a follow-up study of 25,319 women and men in Sweden. Anadolu Kardiyol Derg 2004;4(4):301-5.
27. Fontbonne A. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia 1994;37:953-5.
28. Meigs JB, D'Agostino Sr RB, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study Diabetes 1997;46:1594-600.
29. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationship between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanism. Circulation 2006;113:1888-904.
30. Moncada S, Higgs EA, Hodson HF, et al. The L-arginine:nitric oxide pathway. J Cardiovas Pharmacol 1991;17(Suppl 3):S1-9.
31. Wolpert HA, Steen SN, Istfan NW, Simonson DC. Insulin modulates circulating endothelin-1 levels in humans. Metabolism 1993;42:1027-30. (Pubitemid 23230436)
32. Piatti PM, Monti LD, Conti M, et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 1996;45:316-21. (Pubitemid 26069045)
33. Sowers JR, Frolich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North A 2004;88:63-82.
34. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004;286:1597-602.
35. Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin- aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007;293:2009-23.
36. Smith U, Andersson C, Gustafson B. Adipokines, systemic inflammation and inflamed adipose tissue in obesity and insulin resistance. Int Congr Ser 2007;1303:31-4.
37. Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
38. Lundgren M, Svensson M, Lindmark S, Renström F, Ruge T, Eriksson S. Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia 2007;50:625-33.
39. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3 T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003;278:45777-84. (Pubitemid 37432722)
40. Garcia RG, Perez M, Maas R, Schwedhelm E, Böger RH, López-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol 2007;15:176-8. (Pubitemid 47552581)
41. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
42. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008;14:271-80. (Pubitemid 351711978)
43. Reicher-Reiss H, Jonas M, Boyko V, Shotan A, Goldbourt U, Behar S. Are coronary patients at higher risk with digoxin therapy? An ongoing controversy. Int J Cardiol 1999;68:137-43. (Pubitemid 29083462)
44. Leor J, Goldbourt U, Behar S, et al. Digoxin and mortality in survivors of acute myocardial infarction: observations in patients with low and intermediate risk. Cardiovasc Drugs Ther 1995;9:65-73.
45. Lamounier-Zepter V, Ehrhart-Bornstein M,, Bornstein S. Insulin resistance in hypertension and cardiovascular disease. Best Pract Res Clin Endocrinol Metab 2006;20:355-67. (Pubitemid 44362205)
46. López-Jaramillo P, Pradilla LP, Castillo VR, Lahera V. Socioeconomic pathology as a cause of regional differences in the prevalence of metabolic syndrome and pregnancy-induced hypertension. Rev Esp Cardiol 2007;60:168-78. (Pubitemid 46566970)
47. Lopez-Jaramillo P, Silva SY, Rodriguez-Salamanca N, Duran A, Mosquera W, Castillo V. Are nutrition-induced epigenetic changes the link between socioeconomic pathology and cardiovascular diseases? Am J Ther 2008;15:362-72.
48. Lopez-Jaramillo P. Defining the research priorities to fight the burden of cardiovascular diseases in Latin America. J Hypertens 2008;26:1886-9.
49. Rueda-Clausen C, Lahera V, Calderón V, Bolivar IC, Castillo V, Gutierrez M, et al. Abdominal obesity is associated with changes in the vascular function independent of other cardiovascular risk factors. Int J Cardiol 2010;139:32-41.
50. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998;83:3925-9. (Pubitemid 28513574)
51. Arenas IA, Xu Y, Lopez-Jaramillo P, Davidge ST. Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-alpha. Am J Physiol Cell Physiol 2004;286:779-84.
52. Lopez-Jaramillo P, Garcia RG, Camacho PA, Herrera E, Castillo V. Inter-relationships between body mass index, C-reactive protein and blood pressure in a Hispanic pediatric population. Am J Hypertens 2008;21:527-32. (Pubitemid 351589665)
53. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;19:857-61.
54. Garcia RG, Celedón J, Sierra J, et al. Raised C-reactive protein and impaired flow mediated vasodilation precede the development of preeclampsia. Am J Hypertens 2007;20:98-103. (Pubitemid 46019850)
55. Terán E, Escudero C, Moya W, Florez M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with preeclampsia. Int J Gynaecol Obstet 2001;75:243-9. (Pubitemid 33122080)
56. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131:149-50.